LAG3 and diffuse large B-cell lymphoma: While these data provide initial evidence that blockade of TIM-3 or LAG-3 may induce T cell anti-lymphoma activity, further comprehensive analysis of these effects are needed to fully define the biological activity and potential utility of these compounds to target DLBCL utilizing isogenic cytotoxic CD8+ T cells and tumor cells derived from lymphoma patients.